Solara Active Pharma Sciences Reports Profit Growth in March 2026 Quarter
Solara Active Pharma Sciences reports consolidated net profit of Rs 9.60 crore in the March 2026 quarter
Business Standard
Image: Business Standard
Solara Active Pharma Sciences reported a consolidated net profit of ₹9.60 crore for the quarter ending March 2026, a significant recovery from a net loss of ₹2.10 crore in the same quarter of the previous year. Sales surged by 41.86% to ₹387.29 crore, demonstrating strong performance despite an overall annual net loss for the financial year.
- 01Sales for the quarter increased to ₹387.29 crore, up from ₹273.01 crore in the same quarter last year.
- 02The full-year sales rose by 6.64% to ₹1368.98 crore compared to ₹1283.76 crore in the previous year.
- 03The operating profit margin (OPM) for the quarter was 14.89%, down from 16.62% in March 2025.
- 04The profit before tax (PBT) for the quarter was ₹8.74 crore, compared to a loss of ₹2.10 crore in the same quarter last year.
- 05For the full year, the company reported a net loss of ₹7.41 crore, a decline from a net profit of ₹0.54 crore in the previous year.
Advertisement
In-Article Ad
In the quarter ending March 2026, Solara Active Pharma Sciences achieved a consolidated net profit of ₹9.60 crore, marking a significant turnaround from a net loss of ₹2.10 crore in the same quarter of the previous year. This positive performance was bolstered by a remarkable 41.86% increase in sales, which reached ₹387.29 crore compared to ₹273.01 crore in March 2025. Despite this quarterly success, the company reported an overall net loss of ₹7.41 crore for the fiscal year ending March 2026, in contrast to a net profit of ₹0.54 crore in the prior year. Annual sales also saw a modest rise of 6.64%, totaling ₹1368.98 crore against ₹1283.76 crore in the previous fiscal year. The operating profit margin (OPM) for the quarter stood at 14.89%, a decline from 16.62% in the same quarter last year, indicating some pressure on profitability. The profit before tax (PBT) improved to ₹8.74 crore from a loss in the previous year, reflecting the company's recovery trajectory.
Advertisement
In-Article Ad
The financial recovery of Solara Active Pharma Sciences may lead to increased investor confidence and potential job stability within the company.
Advertisement
In-Article Ad
Reader Poll
Do you think Solara Active Pharma Sciences will continue to improve its financial performance?
Connecting to poll...
More about Solara Active Pharma Sciences
Read the original article
Visit the source for the complete story.